BPC-157 (Body Protection Compound-15) is one of the most extensively studied regenerative peptides in contemporary research. This guide provides a comprehensive scientific overview for laboratory researchers.
What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide derived from a naturally occurring protein found in human gastric juice known as Body Protection Compound (BPC). First isolated from human gastric juice in the 1980s by researchers at the University of Zagreb, the full-length BPC protein (approximately 40 kDa) was found to have protective effects on gastrointestinal tissue. The 15-amino-acid fragment — now known as BPC-157 or PLD-116 — retains and in many cases amplifies the bioactivity of the parent molecule.
This sequence corresponds to residues 17–31 of the native BPC protein and is the most studied fragment in the literature. The synthetic version is stabilised as an acetate salt and is commercially available as a lyophilized powder for research reconstitution.
Known Mechanism of Action
FAK-Paxillin Signalling Axis
BPC-157's primary mechanism is activation of the FAK (focal adhesion kinase) signalling pathway. By promoting FAK phosphorylation at Tyr397 — the critical activation site — BPC-157 enhances focal adhesion dynamics, which are essential for cell migration, proliferation, and survival. Downstream activation of paxillin, a key FAK substrate, modulates actin cytoskeletal reorganisation and facilitates the directional migration of fibroblasts, endothelial cells, and keratinocytes.
Angiogenesis via VEGF and eNOS
BPC-157 is a documented pro-angiogenic agent. Research demonstrates upregulation of VEGF (vascular endothelial growth factor) and its receptors VEGFR1 and VEGFR2, alongside activation of endothelial nitric oxide synthase (eNOS). The resulting NO production drives vasodilation and endothelial cell migration, supporting the formation of functional microvasculature. Angiogenic activity appears within 48–72 hours following administration in animal models.
Growth Factor Modulation
BPC-157 upregulates several growth factor systems including FGF (fibroblast growth factor), IGF-1 (insulin-like growth factor 1), and TGF-β (transforming growth factor beta). These coordinate the proliferative and synthetic activities of fibroblasts and tenocytes during the proliferative phase of tissue repair.
Gastrointestinal Nitric Oxide Pathway
In the gastrointestinal tract, BPC-157 modulates the nitric oxide (NO) system by upregulating eNOS and potentially nNOS, promoting mucosal blood flow, mucus secretion, and epithelial restitution. This pathway is the basis for its original identification as a gastric protective compound and underlies its documented effects on inflammatory bowel disease models.
Key Research Applications
Gastrointestinal & Soft Tissue
BPC-157 has been extensively studied in gastrointestinal research, with published studies demonstrating protection against NSAID-induced enteropathy, ethanol-induced gastric lesions, acetic acid-induced colitis, and intestinal anastomosis healing. In tendon research, rat Achilles tendon models show improved biomechanical properties and accelerated functional recovery.
Muscle & Ligament
Muscle contusion models demonstrate accelerated recovery with BPC-157 administration, mediated through angiogenesis and reduced fibrosis. Systemic administration rather than local injection is hypothesised to produce more uniform tissue distribution and consistent effects across bilateral injury models.
Neurological & Bone
Emerging research explores BPC-157 in peripheral nerve regeneration (rat sciatic nerve models show improved functional recovery) and bone healing (accelerated fracture consolidation in rat tibia models). These applications represent expanding frontiers for BPC-157 research beyond its classical gastrointestinal and soft-tissue domains.
Note: BPC-157 is a research compound sold exclusively for laboratory investigation. It is not approved for human or veterinary use.
Research Protocols & Dosing
Standard protocols in the published literature vary by research model. Typical rodent studies use 10–20 µg/kg/day for gastrointestinal application, 5–10 µg/kg daily for acute injury recovery (7–14 days), and 2.5–5 µg/kg/day for chronic/maintenance protocols.
Common administration routes include: intraperitoneal (IP) injection for systemic effects in gastrointestinal research; subcutaneous (SC) injection for tendon/ligament/muscle recovery research; topical application (eye drops, enema) for localised tissue research.
Stability & Handling
BPC-157 demonstrates good stability as a lyophilized powder. Recommended storage conditions: 2–8°C (refrigerated), protected from light and moisture. In lyophilized form, BPC-157 is stable for 6–12 months under proper refrigeration. Once reconstituted with bacteriostatic water (0.9% benzyl alcohol), it remains stable for 7–14 days at 2–8°C.
BPC-157 is water-soluble and reconstitutes readily. Standard reconstitution: 1–2 mL bacteriostatic water per 5 mg vial, yielding a concentration of 2.5–5 mg/mL. Avoid vortex mixing to prevent foaming and potential peptide damage — gentle swirling until dissolved is recommended.
Quality Standards for BPC-157 Research
For reproducible experimental results, BPC-157 should meet the following specifications: minimum 99% purity verified by HPLC and mass spectrometry; third-party testing by an independent analytical laboratory; published Certificate of Analysis with batch-specific results; and GMP-certified manufacturing origin.
At Element42 Peptides, our BPC-157 is third-party tested via HPLC with COAs published on site for every batch.
This article is provided for scientific and educational purposes only. It does not constitute medical advice or a recommendation for human use. BPC-157 is available exclusively for laboratory research purposes.
Element42 Peptides — Australian owned, third-party tested, 99%+ purity research peptides. View BPC-157 product page.